NIFTY 50

Hope to get regulatory approval for Sputnik V in India by January: RDIF

Updated : November 20, 2020 21:53:49 IST

The COVID-19 pandemic has claimed 1.3 million lives globally so far, but there is some hope now of a vaccine being made available early next year. Pfizer and Moderna have announced a 95 percent efficacy rate following phase three trials of their vaccine candidate.

Russia has said that its Sputnik V vaccine is proving to be 92 percent effective and President Vladimir Putin has suggested that India and China could start manufacturing the Sputnik V vaccine.

However, a preliminary report of the Sputnik V vaccine's efficacy rate is yet to be published in a peer reviewed medical journal. A consignment of the Sputnik V vaccine has arrived in India and trials is set to commence soon.

To discuss more about the Sputnik V vaccine, CNBC-TV18's Parikshit Luthra spoke to Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF).

For more, watch the video.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you